The Leukemologist
Denver, Colorado
Joined October 2012
- Tweets1.4K
- Following342
- Followers1.7K
- Likes2.7K
Daniel Pollyea retweeted
The family of Ian Shelton, PhD, which has deep CU ties, is providing major philanthropic support for an acute myeloid leukemia (AML) clinical trial run by CU Anschutz Cancer Center member Andrew Kent, MD, PhD: news.cuanschutz.edu/cancer-c…
ALT Andrew Kent, MD, PhD, and Ian Shelton, PhD, in the Anschutz Health Sciences Building.
Daniel Pollyea retweeted
Congratulations to Wells Messersmith, MD, the new director of the CU Anschutz Cancer Center.
See the full statement: bit.ly/4yiL1oE
ALT "New Director of the CU Anschutz Cancer Center" in smaller text, broken up by a line of CU gold dots with larger text "Wells Messersmith, MD". There is a cutout photo of Messersmith to the right, with a CU gold dotted background behind him. The CU Anschutz Cancer Center logo is in the bottom left.
Daniel Pollyea retweeted
#AML care is evolving. View a 3-part #ACCC video series to explore practical strategies on diagnosis, targeted therapies, and multidisciplinary #CareCoordination: hubs.li/Q04xHXVG0.
@DanPollyea @cusystem #HematologicMalignancies
Daniel Pollyea retweeted
Congratulations to Sweta and the rest of the team on our new publication in @BCD_AACR exploring the dependence and therapeutic targeting of NAMPT in high-risk MDS stem cells. Thanks to @BloodCancerUtd and Evans Foundation for support! aacrjournals.org/bloodcancer…
Daniel Pollyea retweeted
Before becoming NCI Director, my work focused on blood cancers and cell death. My lab helped lay the groundwork for progress from chemotherapy to targeted therapy. This #BloodCancerAwarenessMonth, I support @theNCI funding more basic research to deliver the next advancement.
ALT Human cells with acute myelocytic leukemia (AML) in the pericardial fluid, shown with an esterase stain at 400x.
Daniel Pollyea retweeted
we are hiring for #Sarcoma Medical Oncology at @CUAnschutz in beautiful Denver, Colorado! Message me for details.
Daniel Pollyea retweeted
The PRISM AML risk model for HMA+VEN is now out in @JCO_ASCO Congratulations to @CLachowiez & all investigators on this huge accomplishment addressing a much needed clinical gap.
We think it’s the Rolls-Royce Phantom of risk models!!!
Bonus: IT HAS A CALCULATOR
Try it out …. you will love it.
prism-aml.com
ascopubs.org/doi/10.1200/JCO…
Daniel Pollyea retweeted
Rolls Royce Phantom!
This is excellent and I do love a calculator!
@OpenMedInsights @allisonoconn @kor_shah
Daniel Pollyea retweeted
The treatment for AML is changing but our risk prognostication hadn’t- until now! Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model | Journal of Clinical Oncology ascopubs.org/doi/full/10.120… Congrats to all authors @JustinWattsMD
Daniel Pollyea retweeted
Finally made it to Stockholm for #EHA26 and starting off right with poached cod & a meeting of the (polyclonal) leukemia minds @beatalleukemia @calliecoombsmd
Daniel Pollyea retweeted
Great to be @ASCO with my colleagues @SAStricklandMD @RitaAssi4 Chun Fong presenting a case panel discussion of TP53 mut MDS, current classification & distinct biologic entity, & current Tx approaches. Our highest unmet need where novel Tx’s are urgently needed. @UNC_Lineberger
Daniel Pollyea retweeted
Thanks so much for hosting me @OSUCCC_James for Grand Rounds. Had a fantastic time in the Buckeye State, thanks for having me @beatalleukemia @AkEisfeld @jamesblachly
Fantastic @OSUHematology Grand Rounds by @LeukDocJZ @UNC_Lineberger on menin inhibitors in AML. It was so great to have you @OSUCCC_James & hang out with our team & the @bcutd_research Beat AML team ! #Buckeye @OSUWexMed
Daniel Pollyea retweeted
Our myeloid sarcoma paper out today…. 🥳
Free to download until Tonight thanks to @_TanyaBondar_ We hope you enjoy reading it.
Some key highlights 👇🏼(but read the paper😉) :
1️⃣Myeloid sarcoma (MS) essentially always originates in the BM and then homes to extramedullary tissues, even when BM is morphologically “normal” 🩸🦴
2️⃣MS evolves through a “Darwinian” molecular evolution with acquisition of additional hits ⚡️ compared to medullary AML
3️⃣MS is underdiagnosed … ctDNA (cell free DNA) is very good at picking up MS, we believe it has great potential as a surveillance tool for MS 🧬
4️⃣ RAS pathway activation (with or without RASp mutations) is a cardinal feature of MS and represents a therapeutic vulnerability 🎯
5️⃣ MS adapts to the tissue microenvironment through upregulation of EMT (epithelial meaenchymal transition) programs and remodels the tissue immune micro environment
@audrey_lasry @BettinaNadorp @AkEisfeld @iannisaifantis1
Now online: RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma doi.org/10.1158/2643-3230.BC…
Daniel Pollyea retweeted
Such a great time in La Jolla at the 30th Annual @MedscapeOnc #ALFLive26 spending time with great friends & colleagues! Will miss this sunset & view! @beatalleukemia @KatieLaiMD_MPH
Daniel Pollyea retweeted
Excited to share that I have been promoted to Professor of Medicine @UNC_SOM @UNC_Lineberger. This milestone could not have been possible w/o the invaluable mentorship from Judy Karp @hopkinskimmel who instilled in me the passion, motivation & drive to improve outcomes in AML.
Daniel Pollyea retweeted
What a great way to end #ALFLive26 with Sasha Perl providing a fantastic overview discussing the pearls (pun intended) and challenges of post-transplant maintenance in AML. @MedscapeOnc
Daniel Pollyea retweeted
Fantastic talk to kick off #ALF26 by @MikkaelSekeres on the pitfalls with our prior trials of Aza combinations in HR-MDS.
Daniel Pollyea retweeted
Paradigm Results put in perspective by Amir Fathi @MedscapeOnc #ALFLIVE26. Great presentation to follow the @ASH_hematology plenary! Now we are all eagerly awaiting the publication with more details and subset analyses.
Daniel Pollyea retweeted
Such an incredible conference highlighting all of the advances and cutting edge therapies for acute leukemia and MDS. Hard to believe this is the 30th annual @MedscapeOnc #ALFLive26 Conference. Kudos to Eytan Stein, @CarrawayHetty & @DanPollyea for running a superb meeting!
Daniel Pollyea retweeted
Incredible tour de force on TP53 mutated AML by David Sallman @MoffittNews at #ALFLIVE26.
